drugset / Trial / NCT03160014
Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment
RandomizedParallel-groupOpen-labelTreatment
Summary
Comparison of the pharmacokinetics/Pharmacodynamics of the SHR3824 in Patients With Mild, Moderate and Severe Hepatic Impairment Compared with Healthy Volunteers.
Timeline
- Start
- 2015-06
- Primary completion
- 2017-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Henagliflozin | Small molecule | 20 mg | Oral |
Indications
No indication recorded.